阿尔茨海默病淀粉样蛋白病理的液体和 PET 标志物。
Fluid and PET biomarkers for amyloid pathology in Alzheimer's disease.
机构信息
Department of Psychiatry, University of Pittsburgh School of Medicine, United States of America.
Neurology Helen Wills Neuroscience Institute, University of California, Berkeley, United States of America; Lawrence Berkeley National Laboratory, Molecular Biophysics and Integrated Bioimaging Functional Imaging Department, Life Sciences Division, United States of America.
出版信息
Mol Cell Neurosci. 2019 Jun;97:3-17. doi: 10.1016/j.mcn.2018.12.004. Epub 2018 Dec 8.
Alzheimer's disease (AD) is characterized by amyloid plaques and tau pathology (neurofibrillary tangles and neuropil threads). Amyloid plaques are primarily composed of aggregated and oligomeric β-amyloid (Aβ) peptides ending at position 42 (Aβ42). The development of fluid and PET biomarkers for Alzheimer's disease (AD), has allowed for detection of Aβ pathology in vivo and marks a major advancement in understanding the role of Aβ in Alzheimer's disease (AD). In the recent National Institute on Aging and Alzheimer's Association (NIA-AA) Research Framework, AD is defined by the underlying pathology as measured in patients during life by biomarkers (Jack et al., 2018), while clinical symptoms are used for staging of the disease. Therefore, sensitive, specific and robust biomarkers to identify brain amyloidosis are central in AD research. Here, we discuss fluid and PET biomarkers for Aβ and their application.
阿尔茨海默病（AD）的特征是淀粉样斑块和 tau 病理学（神经纤维缠结和神经原纤维缠丝）。淀粉样斑块主要由聚集和寡聚β-淀粉样蛋白（Aβ）肽组成，其末端位于 42 位（Aβ42）。阿尔茨海默病（AD）的液体和 PET 生物标志物的发展，使得能够在体内检测到 Aβ 病理学，并标志着对 Aβ 在阿尔茨海默病（AD）中的作用的理解的重大进展。在最近的美国国家老龄化研究所和阿尔茨海默病协会（NIA-AA）研究框架中，AD 是通过在患者生命期间通过生物标志物测量的潜在病理学来定义的（Jack 等人，2018 年），而临床症状用于疾病分期。因此，用于识别脑淀粉样变性的敏感、特异和稳健的生物标志物是 AD 研究的核心。在这里，我们讨论了用于 Aβ 的液体和 PET 生物标志物及其应用。
Zotero 插件